These AI stocks cover voice, logistics, and videos, and all of them are trading at a decent discount to their real value.

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200 million in milestones.

With companies like Pfizer giving possible hope for an end of year vaccine and a recent gap up in IBB​​​​​​​ (Nasdaq Biotechnology ETF), now could be a good time to keep an eye on newer issues in this sector.

Boehringer Ingelheim launched its External Innovation Hub China in Shanghai to increase the company's China R&D partnerships.. The Hub has $508 million to spend on China clinical research, expansion of production sites and research partnerships.